Abstract
Introduction The COVID-19 pandemic has posed a serious threat to global health, with developing nations like India being amongst the worst affected. Chest CT scans play a pivotal role in the diagnosis and evaluation of COVID-19, and certain CT features may aid in predicting the prognosis of COVID-19 illness.
Methods This was a single-centre, hospital-based, cross-sectional study conducted at a tertiary care centre in Northern India during the second wave of the COVID-19 pandemic from May-June 2021. The study included 473 patients who tested positive for COVID-19. A high-resolution chest CT scan was performed within five days of hospitalization, and patient-related information was extracted retrospectively from medical records. Univariable and Multivariable analysis was done to study the predictors of poor outcome.
Results A total of 473 patients were included in the study, with 75.5% being males. The mean total CT score was 29.89 ± 9.06. Fibrosis was present in 17.1% of patients, crazy paving in 3.6%, pneumomediastinum in 8.9%, and pneumothorax in 3.6%. Males had a significantly higher total score, while the patients who survived (30.00 ± 9.55 vs 35.00 v 6.21, p value - <.001), received Steroids at day 2 (28.04 ± 9.71 vs 31.66 ± 7.12, p value – 0.002) or Remdesivir had lower total scores (28.04 ± 9.71 vs 31.66 ± 7.12, p-value – 0.002). Total CT score (aHR 1.05, 95% CI 1.02 – 1.08, p – 0.001), pneumothorax (aHR 1.38, 95 % CI 0.67 – 2.87, p – 0.385), pneumomediastinum (aHR 1.20, 95% CI 0.71 - 2.03, p=0.298) and cardiovascular accident (CVA, aHR 4.75, 95% CI 0.84 – 26.72, p – 0.077) were associated with increased mortality, but the results were not significant after adjusting with other variables on multiple regression analysis.
Conclusion This study identifies several radiological parameters, including fibrosis, crazy paving, pneumomediastinum, and pneumothorax, that are associated with poor prognosis in COVID-19. These findings highlight the role of CT thorax in COVID-19 illness and the importance of timely identification and interventions in severe and critical cases of COVID-19 to reduce mortality and morbidity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the Ethics Committee of the All-India Institute of Medical Sciences, Rishikesh (CTRI/2020/08/027169).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Emails: taranjeetcheema93{at}gmail.com, amitsaroha70{at}gmail.com, arjunkb0013{at}gmail.com, motherprasanna{at}rediffmail.com, sudhirsaxenaindiatimes{at}gmail.com
↵* Joint first author
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
